upper respiratory tract – Page 2 – Communicable Diseases Research

Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost vaccine strategy

Article

Published on 2022-10-012022-11-15
Journal: EBioMedicine
[Category] COVID19(2023년), SARS, 진단, 치료기술,

Comparative Upper Respiratory Tract Transcriptomic Profiling Reveals a Potential Role of Early Activation of Interferon Pathway in Severe COVID-19

Article

Published on 2022-10-012022-11-15
Journal: Viruses
[Category] COVID19(2023년), SARS, 유전자 메커니즘, 치료제,

[키워드] Acute respiratory infection Comparative Coronavirus disease 2019 COVID-19 COVID-19 negative COVID-19 patient COVID-19 patients death driving evaluated Genes Host transcriptional response host-pathogen interactions IFN-I IFN-I response Inflammation initial symptom interferon involved ISG ISGs lung mechanism Mild OAS Potential Profiling progression respiratory Respiratory failure RNA-Seq RNA-sequencing role SARS-CoV-2 severe COVID-19 patient severe COVID-19 patients severe symptom stimulated symptomatic patient the disease tract type I interferon upper upper respiratory tract upregulated viral infection Viral infection. Viral load
[DOI] 10.3390/v14102182 PMC 바로가기

Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology

Article

Published on 2022-09-292022-11-15
Journal: Vaccine
[Category] SARS, 변종, 진단,

[키워드] acute respiratory syndrome Adaptive immune response addition antibodies antibody Beta Cell coronavirus coronavirus disease COVID-19 COVID-19 vaccines CpG cross-protective develop feature Gamma IgA antibody IgG antibody immunopathology Infection initial intranasal intranasal vaccination intranasally investigated less lung Lung eosinophilic immunopathology Lymph node mice mucosa nasal nasal mucosa oligonucleotides pandemic potential risk Prevent Protective protective effect reducing Respiratory disease risk SARS-CoV-2 SARS-CoV-2 variant secretory secretory IgA secretory IgA antibody. serum spike-specific IgG subcutaneous vaccination subcutaneously T helper Th1 Th2 Trimeric spike protein upper respiratory tract vaccination Vaccine variant variants viral challenge virus infection viruses
[DOI] 10.1016/j.vaccine.2022.08.049 PMC 바로가기

A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID

Article

Published on 2022-09-152022-11-16
Journal: Trials
[Category] SARS, 변종,

[키워드] 1:1 applied carrageenan clinical trial COVID-19 COVID-19 infection COVID-19. demonstrated double-blind double-blinded Effect effective Efficacy expressed General population host cell surface host cells in vitro activity include Infection infections initial viral load iota-carrageenan kappa-carrageenan nasal Non-COVID-19 nose and throat occur outcome participant penetrate Placebo placebo-controlled placebo-controlled clinical trial placebo-controlled trial polysaccharide positive PCR Prophylactic Prophylaxis purified questionnaire randomised receptors reduce Research risk SARS-CoV-2 secondary Seroconversion severity severity of COVID-19 shown Sodium chloride Study protocol subsequent Swab Symptom symptom onset thought treatment arm Trial upper respiratory tract utility vaccination Vaccine variant viral entry virus
[DOI] 10.1186/s13063-022-06685-z PMC 바로가기

Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19

Article

Published on 2022-09-142022-11-15
Journal: Critical Care
[Category] SARS, 치료기술,

[키워드] 95% CI adjusted Antigen association AUROC baseline Clinical deterioration Clinical outcome clinical outcomes clinical status Coagulation collected Concentration correlated correlation correlations Course COVID-19 Cutoff death detectable Enrollment Hospital admission hospitalized COVID-19 hospitalized patient host response ICU admission IL-10 IMPROVE In-hospital increase in Inflammation IP-10 marker mechanical ventilation Multiple multiple logistic regression N-antigen Negative predictive value Pathogenesis Patient plasma plasma biomarker plasma concentration plasma sample Positive predictive value Primary outcome Prognosis prognostic progression prospective observational cohort RAGE risk stratification SARS-CoV-2 SARS-CoV-2 N-antigen SARS-CoV-2 nucleocapsid secondary outcome severe disease significantly Study participants subject tested tissue damage unlikely upper respiratory tract Viral antigen Viral RNA was used were assessed were measured WHO WHO ordinal scale with COVID-19 World Health Organization
[DOI] 10.1186/s13054-022-04153-3 PMC 바로가기

Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection

Article

Published on 2022-09-122022-11-15
Journal: Frontiers in Immunology
[Category] SARS, 변종, 진단, 치료기술,

[키워드] absence acute respiratory syndrome Administered administration animal model blocked bronchoalveolar C57BL/6 caused CD4 CD8 coronavirus Coronavirus disease-19 COVID-19 COVID-19 progression current demonstrated effective Efficacy elicited evaluated expressing full-length histopathological IgA antibody IgG immune responses Immunity immunogenic immunogenicity induce intramuscular intranasal intranasal delivery K18-hACE2 transgenic mice Local lung lung lesion lymph nodes mice modified vaccinia virus morbidity and mortality mucosal mucosal immune MVA nasal washe Nasal washes neutralizing antibody parental Prevent pro-inflammatory cytokine PROTECT Protective protective efficacy Protein responses Result S protein SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 transmission SARS-CoV-2 variant SARS-CoV-2 virus SARS-CoV-2-specific immune response serum single dose spleen susceptible systemic immune response systemically T-cell immune response the SARS-CoV-2 Transmission undetectable upper respiratory tract vaccination Vaccine vaccine administration vaccine candidate vaccine candidates vaccine candidates. vaccine dose virus infection
[DOI] 10.3389/fimmu.2022.995235 PMC 바로가기

Moraxella occupied the largest proportion in the nasal microbiome in healthy children, which potential protect them from COVID-19

Research article

Published on 2022-09-012022-10-05
Journal: Microbial pathogenesis
[Category] 바이오마커,

Epigenetic activation of antiviral sensors and effectors of interferon response pathways during SARS-CoV-2 infection

Article

Published on 2022-09-012022-11-15
Journal: Biomedicine & pharmacotherapy = Biomédecine & phar
[Category] COVID19(2023년), SARS, 바이오마커, 진단,

Human Nasal Organoids Model SARS-CoV-2 Upper Respiratory Infection and Recapitulate the Differential Infectivity of Emerging Variants

Article

Published on 2022-08-302022-11-16
Journal: mBio
[Category] SARS, 변종,

Pharmacokinetics and Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Adult Syrian Hamsters

성인 시리아 햄스터에서 중증 급성 호흡기 증후군 코로나바이러스 2 감염의 인간 과면역 정맥 면역글로불린 치료의 약동학 및 효능

Article

Published on 2022-08-242022-09-12
Journal: Clinical Infectious Diseases: An Official Publicat
[Category] SARS, 진단,

[키워드] accelerated acute respiratory syndrome anti-SARS-CoV-2 antibody binding Blood blood sample challenge clearance clinical trial coronavirus coronavirus 2 coronavirus disease COVID-19 different time points Donor dose Efficacy hamster hamsters hospitalized patient Human hyperimmune immune immune globulin Immunoglobulin investigated Lower respiratory tract lung tissue lung tissue sample Messenger RNA nasal parameters pharmacokinetic pharmacokinetics PK parameter plasma polymerase chain reduction in respiratory resulting SARS-CoV-2 SARS-CoV-2 virus single dose the SARS-CoV-2 virus therapy tracheal treating SARS-CoV-2 infection upper respiratory tract used to calculate viral replication viral replication. were given with COVID-19
[DOI] 10.1093/cid/ciab854 PMC 바로가기 [Article Type] Article